Ennecor Spółka z Ograniczoną Odpowiedzialnością (KRS 0000972407, NIP 5732935164) is a Polish company, headquartered in Gliwice, Śląskie voivodeship. Ennecor operates in: Other research and experimental development on natural sciences and engineering (PKD 72.19.Z). Industry: Research and development. The company has been listed in the National Court Register since May 18, 2022. Ennecor's most recently reported net revenue was 5.1 M PLN for 2025.
Negative equity
Negative equity in 2 of 4 available reporting years.
No arrears identified in the analysed sources
No arrears or bankruptcy proceedings identified in the analysed sources.
Business profile - Ennecor
Identity
- Name
- Ennecor Spółka z Ograniczoną Odpowiedzialnością
- Legal form
- SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
- Founded
- May 18, 2022
- Registry status as of
- July 13, 2026
- Latest entry
- July 13, 2026
- Founding act
- 16.05.2022R.
Articles of association history (3)
- May 16, 2022: 16.05.2022R.
- November 6, 2023: 06.11.2023 KANCELARIA NOTARIALNA W RACIBORZU, NOTARIUSZ AGATA RABCZUK, NOTARIUSZ AGNIESZKA RACZEK, REP. A 8972/2023, ZMIANA UMOWY SPÓŁKI POPRZEZ UCHYLENIE JEJ DOTYCHCZASOWEJ TREŚCI I PRZYJĘCIE NOWEGO BRZMIENIA, 21.11.2023 KANCELARIA NOTARIALNA W RACIBORZU, NOTARIUSZ AGATA RABCZUK, NOTARIUSZ AGNIESZKA RACZEK, REP. A 9466/2023, ZMIANA UMOWY SPÓŁKI Z DNIA 16.05.2022 ZMIENIONY NASTĘPNIE DNIA 06.11.2023 POPRZEZ WYKREŚLENIE Z PARAGRAFU 7 UST. 1 PKT. 2) PUNKTÓW: G, H, ORAZ ZMIANĘ W PARAGRAFIE 23 UST. 1 PKT.F
- September 20, 2024: 20.09.2024R., NOTARIUSZ AGATA RABCZUK, NOTARIUSZ AGNIESZKA RACZEK, KANCELARIA NOTARIALNA W RACIBORZU, REP. A NR 8282/2024 - ZMIENIONO: §9 UST.1, §23 UST.1, §26; - DODANO: §17 UST. 5 I 6, §23 UST. 5,
Activities
Other activities
Address and contact
- Address
- UL. WINCENTEGO POLA, 27, 44-100, GLIWICE, POLSKA
- Voivodeship
- ŚLĄSKIE
- District
- GLIWICE
- Not disclosed in the registry
- Website
- Not disclosed in the registry
- E-delivery address
- AE:PL-60468-58016-RDFGS-12
Risk and payment profile - Ennecor
Credibility rating
24.2 / 100
Poor credibility
Insolvency risk
Moderate
Significant formal threat
Closure risk
29
/ 100
Risk comparison - scale 0 (safe) → 100 (critical)
Organisational stability signals
No instability signals - ownership, management, PKD codes and company name remain relatively stable.
Shareholder changes
2
2/4 yrs
Board changes
2
2/4 yrs
PKD changes
1
1/4 yrs
Name changes
1
1/4 yrs
Data from 4 years of registry activity.
Credibility history
Payment reliability score from 2022–2025
Current: E (24/100)
Trend: deteriorating (-24.8 pts/year)
Bardzo słaba wiarygodność płatnicza – współpraca handlowa wiąże się z wysokim ryzykiem braku zapłaty.
Trade credit limit history
Standard limit from 2022–2025
Current: 282.7 K PLN
Safe: 48.1 K PLN
Operational status - Ennecor
Founded
May 18, 2022
4 years in operation
Legal form
SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
Registry: RejP
Headquarters
GLIWICE
ŚLĄSKIE
Primary PKD
72.19.Z
Other research and experimental development on natural sciences and…
Share capital
20.0 K PLN
100 shares total
Shareholders
4
shareholders
Board
2 people
Proxies: 1
Filed years
4 years
2022–2025 · profitable: 1/4
Registry entries
21
latest: July 13, 2026
Risk signals
Revenue
5.1 M PLN
2025
Net profit
-686.1 K PLN
2025
Assets
5.0 M PLN
2025
Equity
-1.5 M PLN
2025
EBITDA
-420.6 K PLN
2025
Companies in the same location
Public procurement
Trademarks
Reviews
Rate business credibility - Ennecor.
No ratings
Related articles
News
Bioceltix in the final EMA dialogue phase: BCX-CM-J could become Europe's first veterinary cell-therapy drug for dogs
Wrocław-based Bioceltix S.A. (KRS 0000744521) entered Q2 2026 in the final EMA dialogue phase on BCX-CM-J – potentially Europe's first veterinary cell-therapy drug based on mesenchymal stem cells, for dogs with osteoarthritis. Responses to the EMA's final questions are due in May 2026; a CVMP recommendation and marketing authorisation are possible in Q3/Q4 2026. A pre-commercial biotech: it closed 2024 with a PLN 14.9m loss on zero revenue and PLN 33.6m of cash at year-end. Trigon DM maintains a buy rating with a PLN 127.2 price target.
News
Captor Therapeutics: PLN 36m of cash at 30 September 2025, runway to mid-2026 – clinical data versus the cash clock
Wrocław-based Captor Therapeutics S.A. (KRS 0000756383) – a pre-commercial biotech specialising in targeted protein degradation (TPD) – closed Q3 2025 with PLN 36m of cash and grants securing funding to mid-2026. CT-01 (hepatocellular carcinoma) entered Phase I, with the first patient dosed at the Barcelona Clinic Liver Cancer. CT-03, an MCL-1 degrader, is close to clinical entry. Without a new R&D partnership or share issue in 2026, the company will need additional financing.
